AEON Biopharma (AEON) Non Operating Income (2021 - 2026)
AEON Biopharma (AEON) posted Non Operating Income of -$31.6 million for Q4 2025, down 1446.5% sequentially from -$2.0 million in Q3 2025, and down 818.28% YoY from $4.4 million in Q4 2024.
AEON Biopharma (AEON) Non Operating Income (2021 - 2026) Analysis & Trends
AEON Biopharma has reported Non Operating Income for 5 years, with the latest figure at -$31.6 million in Q4 2025.
- Quarterly Non Operating Income fell 818.28% year-over-year to -$31.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.4 million (up 14.73% YoY) and the FY2025 annual result came in at -$26.4 million, up 14.72% from the prior year.
- Non Operating Income declined to -$31.6 million in Q4 2025 per AEON's latest filing, from -$2.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $10.6 million in Q2 2024 and troughed at -$43.9 million in Q1 2024.
- A 5-year average of -$4.3 million and a median of -$1.4 million in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 2566.1% in 2023, then soared 855.61% in 2024.
- Over 5 years, Non Operating Income stood at $1.1 million in 2021, then plunged by 1822.8% to -$19.5 million in 2022, then climbed by 28.33% to -$14.0 million in 2023, then soared by 131.46% to $4.4 million in 2024, then sank by 818.28% to -$31.6 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$31.6 million, -$2.0 million, and -$2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | AEON Biopharma | 9.71 Mn | 6.28 Mn | - | 4.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.76 Mn |
| Dec 31, 2025 | -31.63 Mn |
| Sep 30, 2025 | -2.05 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Mar 31, 2025 | 9.56 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | -2.16 Mn |
| Jun 30, 2024 | 10.64 Mn |
| Mar 31, 2024 | -43.87 Mn |
| Sep 30, 2023 | -14.00 Mn |
| Jun 30, 2023 | -1.41 Mn |
| Mar 31, 2023 | -4.59 Mn |
| Dec 31, 2022 | -19.53 Mn |
| Sep 30, 2022 | -525,000.00 |
| Jun 30, 2022 | 2.31 Mn |
| Mar 31, 2022 | 3.16 Mn |
| Dec 31, 2021 | 1.13 Mn |
| Sep 30, 2021 | 6.11 Mn |
| Jun 30, 2021 | -3.63 Mn |
| Mar 31, 2021 | 6.52 Mn |